Drugs / αPD-1-mesoCAR-T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03615313 | Aug 2018 → Aug 2020 | neoplasm | Shanghai Cell Therapy Research Institute | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | αPD-1-mesoCAR-T cells | “The modified T cells were called αPD-1-mesoCAR-T cells.” PMID 33589520 ↗ Feb 2021 |
| Action | Deplete | “MesoCAR-T can specifically and effectively kill the mesothelin positive cancer cells” NCT03615313 ↗ |
| Modality | Cell therapy | “autologous T cells that contained sequences encoding single-chain variable fragments specific for MSLN and full-length antibody for PD-1 (αPD-1).” PMID 33589520 ↗ Feb 2021 |
| Route | Intravenous | “returned to the patients by venous transfusion therapy.” NCT03615313 ↗ |
| Target | MSLN | “Targeting MSLN by antibodies or chimeric antigen receptor-modified T (CAR-T) cells” PMID 33589520 ↗ Feb 2021 |